Futura Strikes Deal To Commercialize Erectile Dysfunction Gel In Middle East
Executive Summary
UK R&D firm Futura Medical strikes third commercial agreement for its drug-free erectile dysfunction treatment MED3000, this time with Switzerland’s Labatec Pharma, which will take the drug-free gel to the Middle East.
You may also be interested in...
Labatec Gets Approval To Market Futura’s Eroxon Erectile Dysfunction Gel In Saudi Arabia
Futura Medical's MED3000 erectile dysfunction gel gets OTC approval in the Kingdom of Saudi Arabia, where Switzerland's Labatec Pharma has the rights to commercialize the product under the Eroxon brand.
Cooper Preparing European Launch Of Eroxon OTC Erectile Dysfunction Gel
France's Cooper Consumer Health is aiming to get Futura's drug-free OTC Eroxon erectile dysfunction gel on European shelves in the next few months.
Futura All Set For US FDA De Novo Application For Eroxon OTC ED Treatment
Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.